The peritoneal dialysis market size was USD 4.10 Billion in 2021 and is expected to register a revenue CAGR of 5.5% during the forecast period. Large deficit of kidneys for transplantation in patients, rising prevalence of chronic kidney disease among patients due to diabetes, surge in End-Stage Renal Disease (ESRD) patients globally, and rapid technological advancement in the healthcare industry are major factors responsible for the revenue growth of the market over the forecast period.
The shortage of kidneys for transplantation is one of the major concerns and continues to be a public health crisis globally. According to reports more than 90,000 patients in the U.S. are waiting for kidney transplantation, but only about 20,000 transplants are performed each year. The advantage of peritoneal dialysis is that it may be done at home and does not require frequent trips to a dialysis facility. In addition, peritoneal dialysis patients have fewer dietary and fluid limitations than hemodialysis patients. This is expected to raise the demand for peritoneal dialysis and hence drive the revenue growth of the market in the coming years.
Chronic Kidney Disease (CKD) has surged significantly in recent years which can be attributed to the rising prevalence of diabetes and high blood pressure among patients. According to the Centers for Disease Control and Prevention (CDC) around 15% of U.S. adults or 37 million people, are estimated to have CKD which is more prevalent in older people aged 65 years or above. CKD becomes critical over time and increases the chances of having heart disease and stroke. This has led to rising demand for peritoneal dialysis which is driving the market revenue growth considerably.
Request a Sample@ https://qyresearchmedical.com/sample/119027
Driver: Surge in End-Stage Renal Disease (ESRD) patients globally
End-Stage Renal Disease (ESRD) is a medical illness in which a person’s kidneys stop working permanently, necessitating either a kidney transplant or a continuous course of long-term dialysis to sustain life. A surge in End-Stage Renal Disease (ESRD) patients globally are expected to raise the demand for peritoneal dialysis. The increasing prevalence of Chronic Kidney Disease (CKD) and its progression to End-Stage Renal Disease (ESRD) has led to a significant rise in premature mortality. Hemodialysis (HD) may be considered, although each HD procedure and the execution of vascular access require rigorous coagulation factor therapy. Only when inserting the peritoneal catheter is coagulation replacement therapy necessary for Peritoneal Dialysis (PD). When the kidneys are unable to efficiently filter the blood, peritoneal dialysis is a treatment option. With the aid of a dialysate solution that cycles in and out through an abdominal catheter, blood vessels in the peritoneum, the lining of the stomach, filter much like the kidneys during peritoneal dialysis. Continuous Ambulatory Peritoneal Dialysis (CAPD) is peritoneal dialysis that can be performed continuously throughout the day manually and without a machine. The patient infuses his or her abdomen with the dialysis fluid, which is then drained. The liquid flows through the tube and into and out of the stomach thanks to gravity. Patients undergoing CAPD are unrestricted in their daily activities while the dialysis solution remains in their bellies in between exchanges. While Continuous Cycling Peritoneal Dialysis (CCPD), also called Automated Peritoneal Dialysis (APD) involves a machine called an automated cycler and performs three to five exchanges at night while the patient sleeps. These factors are expected to raise the demand for peritoneal dialysis and are therefore driving the revenue growth of the market.
Restraint: Higher risk of infection for patients
Peritoneal dialysis is needed to be carried out quite frequently and requires a cather to be placed permanently outside the body. In addition, higher risks of peritonitis, hypoproteinemia, and hypertriglyceridemia are major factors restraining the growth of the market. Furthermore, CAPD is a time-consuming procedure and requires sufficient space for storing home supplies. These factors are hampering the revenue growth of the market.
Based on type, the peritoneal dialysis market has been segmented into Continuous Ambulatory Peritoneal Dialysis (CAPD), and Automated Peritoneal Dialysis (APD). The continuous Ambulatory Peritoneal Dialysis (CAPD) segment is expected to register significant revenue growth over the forecast period. CAPD is peritoneal dialysis that can be performed continuously throughout the day manually and without a machine. The procedure is novel for treating end-stage renal illness. It has the advantages of better blood pressure control, a noticeable improvement in anemia, and an unrestricted diet. It also offers a larger clearance of heavier molecular weight drugs than during hemodialysis. The main difference between CAPD and APD is the use of a machine, called a cycler which performs the exchanges. CAPD does not use a cycler whereas APD uses a cycler, however, both therapies are designed to be done over 24 hours. These factors are contributing to the revenue growth of the segment.
Based on end-user, peritoneal dialysis market has been segmented into home-based dialysis and hospital-based dialysis. Home-based dialysis segment is expected to register a significant growth rate over the forecast period. Peritoneal Dialysis is normally carried out at home or in any other clean confined space. Since Peritoneal Dialysis treatments are given at regular intervals, the waste and toxins present in the patient’s blood don’t have much time to accumulate in between sessions. Less medication and fewer dietary restrictions may also result from home peritoneal dialysis. It takes 3 to 5 exchanges per day to complete continuous ambulatory peritoneal dialysis without a machine. The advantage of CAPD is that the patient can administer the dialysis while at home, at work, or on the road. This is driving the revenue growth of the segment.
Based on product, the global peritoneal dialysis market is segmented into peritoneal dialysis solutions, devices, peritoneal dialysis sets, catheters, and others. The peritoneal dialysis solution segment accounted for a major revenue share in 2021. Dialysis solution comes in bags of various sizes ranging from 1.5-, 2-, 2.5-, or 3 liters. Dextrose or icodextrin, together with minerals, are present as the solution to draw waste products and surplus fluid from the circulation to the abdomen. The concentrations of dextrose or icodextrin vary depending on the solution. A high concentration of glucose is present in a standard peritoneal dialysis fluid as an osmotic agent. The amount of ultrafiltration is determined by the amount of glucose solution exchanged, the amount of time the fluid stays in the peritoneal cavity, and the unique peritoneal membrane features of each patient. These factors are expected to drive market revenue growth over the forecast period.
North America accounted for the largest revenue share in 2021. This can be attributed to the increasing prevalence of Chronic Kidney Disease (CKD) and End-Stage Renal Disease (ESRD). Nearly 786,000 people in the United States are living with End-Stage Renal Disease (ESRD), with 71% on dialysis. The increasing number of patients with diabetes and high blood pressure has led to a surge in patients suffering from CKD. In 2019, 37.3 million people in the U.S., or 11.3% of the population, had diabetes. This has led to a rapidly rising demand for peritoneal dialysis among kidney patients and is thereby expected to drive the revenue growth of the market in the region. In addition, the presence of major manufacturers such as Baxter, DaVita Inc., and other leading manufacturers has led to increased availability of a wide range of dialysis products at competitive pricing which is expected to propel the revenue growth of the market.
The peritoneal dialysis market in Europe is expected to register a robust growth rate over the forecast period. This can be attributed to the wide proliferation of health insurance businesses across various countries in Europe. According to the population coverage of the private and statutory health insurance systems, health insurers and the government in Germany split the cost of medical expenses. Similarly, in the Netherlands, health insurance is entirely privatized, although government reinsurance and risk-equalization policies minimize losses for health insurers. Despite differences in the ownership structure of health delivery systems, Universal Health Coverage (UHC) exists in every country across Europe. This can support patients suffering from end-stage renal disease in getting proper treatment through peritoneal dialysis and hence drive the revenue growth of the market.
The peritoneal dialysis market in Asia Pacific accounted steady growth rate over the forecast period owing to the rapid technological advancement in the healthcare industry and increasing public and private expenditure in healthcare facilities. The Government of India introduced the Pradhan Mantri National Dialysis Program (PMNDP) under which dialysis services are provided to all patients Below the Poverty Line (BPL) at district hospitals in the country for free of cost. Similarly, under Pradhan Mantri Jan Arogya Yojana (PMJAY), dialysis is one of the most claimed packages under the scheme. In addition, the Government of China has taken various policy measures to increase the covered medical services for patients with end-stage kidney disease because of this currently there has been a significant rise in patients receiving peritoneal dialysis in China, which represents about 20% of the total dialysis. These factors are expected to sustain the growth of the market in the region over the forecast period.
The competitive landscape of the global peritoneal dialysis market is consolidated with a few key players operating on global and regional levels. Key players are engaged in strategic alliances to expand their respective portfolios and gain a robust footing in the global market. Major companies in the global market report include Baxter International, B. Braun SE, Nipro, Medtronic, DaVita Inc., Fresenius Medical Care, Medical Components, Inc., NephroPlus, Huaren Pharmaceutical Co., Ltd., NxStage Medical, Inc., and Mitra Industries Pvt ltd
- On 24 August 2022, Fresenius Medical Care, has closed the three-way merger including Fresenius Health Partners, the value-based care division of Fresenius Medical Care North America. The transaction has received regulatory clearance in the U.S. The newly formed business will operate under InterWell Health, and it combines the proficiency in renal care value-based contracting and the performance of Fresenius Health Partners.
Segments Covered in the report
This report offers historical data and forecasts revenue growth at a global, regional, and country level, and provides analysis of market trends in each of the sub-segments from 2019 to 2030. For the purpose of this report, Reports and Data has segmented the peritoneal dialysis market based on type, end-user, product, and region:
Peritoneal Dialysis Market Report Scope
Segments covered By Type Outlook, End-User Outlook, Product Outlook, Regional Outlook
By Type Outlook
Continuous Ambulatory Peritoneal Dialysis (CAPD)
Automated Peritoneal Dialysis (APD)
By End-User Outlook
By Product Outlook
Peritoneal dialysis solution
Peritoneal dialysis set
Middle East & Africa
Buy quantitative research Report at discounted price – USD 1500 https://qyresearchmedical.com/report/checkout/119027/1500
You can place an order or ask any questions, please feel free to contact email@example.com | +1 9197 992 333
QYResearch Medical has more than 4000 global well-known customers, covering more than 30 industries including pharmaceuticals, medical technology & devices, healthcare services etc. Company services cover one-stop solution as Data-Analysis-Suggestion-Consulting Implementation. Research regions cover North America, Europe, Latin America, Middle East and Africa, Asia- Pacific.
For Latest Update Follow Us: